<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />



<title>Trial Definition</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>



<style type="text/css">
code {
white-space: pre;
}
.sourceCode {
overflow: visible;
}
</style>
<style type="text/css" data-origin="pandoc">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
{ counter-reset: source-line 0; }
pre.numberSource code > span
{ position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
{ content: counter(source-line);
position: relative; left: -1em; text-align: right; vertical-align: baseline;
border: none; display: inline-block;
-webkit-touch-callout: none; -webkit-user-select: none;
-khtml-user-select: none; -moz-user-select: none;
-ms-user-select: none; user-select: none;
padding: 0 4px; width: 4em;
color: #aaaaaa;
}
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa; padding-left: 4px; }
div.sourceCode
{ }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } 
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.at { color: #7d9029; } 
code span.bn { color: #40a070; } 
code span.bu { color: #008000; } 
code span.cf { color: #007020; font-weight: bold; } 
code span.ch { color: #4070a0; } 
code span.cn { color: #880000; } 
code span.co { color: #60a0b0; font-style: italic; } 
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.do { color: #ba2121; font-style: italic; } 
code span.dt { color: #902000; } 
code span.dv { color: #40a070; } 
code span.er { color: #ff0000; font-weight: bold; } 
code span.ex { } 
code span.fl { color: #40a070; } 
code span.fu { color: #06287e; } 
code span.im { color: #008000; font-weight: bold; } 
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.kw { color: #007020; font-weight: bold; } 
code span.op { color: #666666; } 
code span.ot { color: #007020; } 
code span.pp { color: #bc7a00; } 
code span.sc { color: #4070a0; } 
code span.ss { color: #bb6688; } 
code span.st { color: #4070a0; } 
code span.va { color: #19177c; } 
code span.vs { color: #4070a0; } 
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } 
</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    var j = 0;
    while (j < rules.length) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") {
        j++;
        continue;
      }
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') {
        j++;
        continue;
      }
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>



<style type="text/css">

div.csl-bib-body { }
div.csl-entry {
clear: both;
}
.hanging div.csl-entry {
margin-left:2em;
text-indent:-2em;
}
div.csl-left-margin {
min-width:2em;
float:left;
}
div.csl-right-inline {
margin-left:2em;
padding-left:1em;
}
div.csl-indent {
margin-left: 2em;
}
</style>

<style type="text/css">body {
background-color: #fff;
margin: 1em auto;
max-width: 700px;
overflow: visible;
padding-left: 2em;
padding-right: 2em;
font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;
font-size: 14px;
line-height: 1.35;
}
#TOC {
clear: both;
margin: 0 0 10px 10px;
padding: 4px;
width: 400px;
border: 1px solid #CCCCCC;
border-radius: 5px;
background-color: #f6f6f6;
font-size: 13px;
line-height: 1.3;
}
#TOC .toctitle {
font-weight: bold;
font-size: 15px;
margin-left: 5px;
}
#TOC ul {
padding-left: 40px;
margin-left: -1.5em;
margin-top: 5px;
margin-bottom: 5px;
}
#TOC ul ul {
margin-left: -2em;
}
#TOC li {
line-height: 16px;
}
table {
margin: 1em auto;
border-width: 1px;
border-color: #DDDDDD;
border-style: outset;
border-collapse: collapse;
}
table th {
border-width: 2px;
padding: 5px;
border-style: inset;
}
table td {
border-width: 1px;
border-style: inset;
line-height: 18px;
padding: 5px 5px;
}
table, table th, table td {
border-left-style: none;
border-right-style: none;
}
table thead, table tr.even {
background-color: #f7f7f7;
}
p {
margin: 0.5em 0;
}
blockquote {
background-color: #f6f6f6;
padding: 0.25em 0.75em;
}
hr {
border-style: solid;
border: none;
border-top: 1px solid #777;
margin: 28px 0;
}
dl {
margin-left: 0;
}
dl dd {
margin-bottom: 13px;
margin-left: 13px;
}
dl dt {
font-weight: bold;
}
ul {
margin-top: 0;
}
ul li {
list-style: circle outside;
}
ul ul {
margin-bottom: 0;
}
pre, code {
background-color: #f7f7f7;
border-radius: 3px;
color: #333;
white-space: pre-wrap; 
}
pre {
border-radius: 3px;
margin: 5px 0px 10px 0px;
padding: 10px;
}
pre:not([class]) {
background-color: #f7f7f7;
}
code {
font-family: Consolas, Monaco, 'Courier New', monospace;
font-size: 85%;
}
p > code, li > code {
padding: 2px 0px;
}
div.figure {
text-align: center;
}
img {
background-color: #FFFFFF;
padding: 2px;
border: 1px solid #DDDDDD;
border-radius: 3px;
border: 1px solid #CCCCCC;
margin: 0 5px;
}
h1 {
margin-top: 0;
font-size: 35px;
line-height: 40px;
}
h2 {
border-bottom: 4px solid #f7f7f7;
padding-top: 10px;
padding-bottom: 2px;
font-size: 145%;
}
h3 {
border-bottom: 2px solid #f7f7f7;
padding-top: 10px;
font-size: 120%;
}
h4 {
border-bottom: 1px solid #f7f7f7;
margin-left: 8px;
font-size: 105%;
}
h5, h6 {
border-bottom: 1px solid #ccc;
font-size: 105%;
}
a {
color: #0033dd;
text-decoration: none;
}
a:hover {
color: #6666ff; }
a:visited {
color: #800080; }
a:visited:hover {
color: #BB00BB; }
a[href^="http:"] {
text-decoration: underline; }
a[href^="https:"] {
text-decoration: underline; }

code > span.kw { color: #555; font-weight: bold; } 
code > span.dt { color: #902000; } 
code > span.dv { color: #40a070; } 
code > span.bn { color: #d14; } 
code > span.fl { color: #d14; } 
code > span.ch { color: #d14; } 
code > span.st { color: #d14; } 
code > span.co { color: #888888; font-style: italic; } 
code > span.ot { color: #007020; } 
code > span.al { color: #ff0000; font-weight: bold; } 
code > span.fu { color: #900; font-weight: bold; } 
code > span.er { color: #a61717; background-color: #e3d2d2; } 
</style>




</head>

<body>




<h1 class="title toc-ignore">Trial Definition</h1>



<div id="defining-the-design" class="section level2">
<h2>Defining the design</h2>
<p>A CRM study consists of six basic elements:</p>
<ul>
<li>The dose grid</li>
<li>The dose-toxicity model</li>
<li>The increment rule_<sup>1</sup></li>
<li>The dose recommendation rule<sup>1</sup></li>
<li>The cohort size<sup>1</sup></li>
<li>The stopping rule</li>
</ul>
<p>1: Note that in <code>crmPack</code>, the increment, dose selection
and cohort size rules are collectively known as the <i>escalation
rules</i>.</p>
<p>There are many, many possible choices for each element. In this
introduction, we make simple choices for the value of each element.</p>
<p>We start by loading the <code>crmPack</code> package …</p>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(crmPack)</span></code></pre></div>
<p>… and defining each element in turn.</p>
<div id="the-dose-grid" class="section level3">
<h3>The dose grid</h3>
<p>First, we list the doses that <em>might</em> be used during the
trial.</p>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Define the dose grid.</span></span>
<span id="cb2-2"><a href="#cb2-2" aria-hidden="true" tabindex="-1"></a>empty_data <span class="ot">&lt;-</span> <span class="fu">Data</span>(<span class="at">doseGrid =</span> <span class="fu">c</span>(<span class="dv">1</span>, <span class="dv">3</span>, <span class="dv">9</span>, <span class="dv">20</span>, <span class="dv">30</span>, <span class="dv">45</span>, <span class="dv">60</span>, <span class="dv">80</span>, <span class="dv">100</span>))</span></code></pre></div>
<p>There is no commitment to use every dose in the grid. Here we define
a grid of 9 doses ranging between 1 and 100. <code>crmPack</code> is
agnostic with respect to the units used to measure the doses. The only
requirements are that the dose grid is ordered and one dimensional.</p>
<p>Additional doses can be added whilst the trial is running. This will
not affect the validity of the results of the trial prior to the
addition, but will probably affect the trial’s operating
characteristics.</p>
</div>
<div id="the-dose-toxicity-model" class="section level3">
<h3>The dose toxicity model</h3>
<p>Next, define the dose toxicity model.</p>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Initialize the CRM model.</span></span>
<span id="cb3-2"><a href="#cb3-2" aria-hidden="true" tabindex="-1"></a>model <span class="ot">&lt;-</span> <span class="fu">LogisticLogNormal</span>(</span>
<span id="cb3-3"><a href="#cb3-3" aria-hidden="true" tabindex="-1"></a>  <span class="at">mean =</span> <span class="fu">c</span>(<span class="sc">-</span><span class="fl">0.85</span>, <span class="dv">1</span>),</span>
<span id="cb3-4"><a href="#cb3-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">cov =</span> <span class="fu">matrix</span>(<span class="fu">c</span>(<span class="dv">1</span>, <span class="sc">-</span><span class="fl">0.5</span>, <span class="sc">-</span><span class="fl">0.5</span>, <span class="dv">1</span>), <span class="at">nrow =</span> <span class="dv">2</span>),</span>
<span id="cb3-5"><a href="#cb3-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">ref_dose =</span> <span class="dv">56</span></span>
<span id="cb3-6"><a href="#cb3-6" aria-hidden="true" tabindex="-1"></a>)</span></code></pre></div>
<p>In <code>crmPack</code>, the <code>LogisticLogNormal</code> class
fits a model of the following form:</p>
<p><span class="math display">\[log(\frac{p_i}{1 - p_i}) = \alpha +
\beta (d_i - d^*)\]</span></p>
<p>where <span class="math inline">\(d^*\)</span> is a reference dose
(specified by the <code>ref_dose</code> argument to the
<code>LogisticLogNormal</code> function above) and the prior joint
distribution of <span class="math inline">\(\alpha\)</span> and <span class="math inline">\(\beta\)</span> is</p>
<p><span class="math display">\[\begin{bmatrix}
\alpha \\
log(\beta)
\end{bmatrix}   \sim
N\begin{pmatrix}
\begin{bmatrix}
\mu_{\alpha}\\ \mu_{\beta}
\end{bmatrix}   ,
\begin{bmatrix}
\sigma_{\alpha\alpha} &amp; \sigma_{\alpha\beta} \\
\sigma_{{\beta\alpha}} &amp; \sigma_{\beta\beta}
\end{bmatrix}   
\end{pmatrix}.
\]</span></p>
<p>The mean and covariance matrices are defined by the <code>mean</code>
and <code>cov</code> parameters to the <code>LogisticLogNormal</code>
call. So the code above defines the prior joint distribution of <span class="math inline">\(\alpha\)</span> and <span class="math inline">\(log(\beta)\)</span> to be</p>
<p><span class="math display">\[
N\begin{pmatrix}
\begin{bmatrix}
-0.85\\0
\end{bmatrix}   ,
\begin{bmatrix}
1 &amp; -0.5 \\
-0.5 &amp; 1
\end{bmatrix}   
\end{pmatrix}.
\]</span></p>
<p>It is easy to obtain a visual representation of the prior:</p>
<div class="sourceCode" id="cb4"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb4-1"><a href="#cb4-1" aria-hidden="true" tabindex="-1"></a>vignetteMcmcOptions <span class="ot">&lt;-</span> <span class="fu">McmcOptions</span>(<span class="at">burnin =</span> <span class="dv">100</span>, <span class="at">step =</span> <span class="dv">2</span>, <span class="at">samples =</span> <span class="dv">1000</span>)</span>
<span id="cb4-2"><a href="#cb4-2" aria-hidden="true" tabindex="-1"></a>prior_samples <span class="ot">&lt;-</span> <span class="fu">mcmc</span>(</span>
<span id="cb4-3"><a href="#cb4-3" aria-hidden="true" tabindex="-1"></a>  <span class="at">data =</span> empty_data,</span>
<span id="cb4-4"><a href="#cb4-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">model =</span> model,</span>
<span id="cb4-5"><a href="#cb4-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">options =</span> vignetteMcmcOptions</span>
<span id="cb4-6"><a href="#cb4-6" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb4-7"><a href="#cb4-7" aria-hidden="true" tabindex="-1"></a><span class="fu">plot</span>(prior_samples, model, empty_data)</span></code></pre></div>
<p><img src="data:image/png;base64,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" /><!-- --></p>
</div>
<div id="the-escalation-rules" class="section level3">
<h3>The escalation rules</h3>
<div id="the-maximum-increment" class="section level4">
<h4>The maximum increment</h4>
<p>Now, we define the maximum possible increment between the dose used
in current cohort and the dose used in the next, regardless of likely
toxicity.</p>
<div class="sourceCode" id="cb5"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb5-1"><a href="#cb5-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Choose the rule for dose increments.</span></span>
<span id="cb5-2"><a href="#cb5-2" aria-hidden="true" tabindex="-1"></a>my_increments <span class="ot">&lt;-</span> <span class="fu">IncrementsRelative</span>(</span>
<span id="cb5-3"><a href="#cb5-3" aria-hidden="true" tabindex="-1"></a>  <span class="at">intervals =</span> <span class="fu">c</span>(<span class="dv">0</span>, <span class="dv">30</span>),</span>
<span id="cb5-4"><a href="#cb5-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">increments =</span> <span class="fu">c</span>(<span class="dv">1</span>, <span class="fl">0.5</span>)</span>
<span id="cb5-5"><a href="#cb5-5" aria-hidden="true" tabindex="-1"></a>)</span></code></pre></div>
<p>The rule we have chosen here defines the maximum possible increment
in terms of multiples of the highest dose so far administered: for doses
greater than <code>0</code> and less than <code>20</code>, the maximum
increment is 100 x (1 + 1)%, or 200% of the highest dose used so far.
For doses of <code>20</code> or more, the maximum increment is 100 x (1
+ 0.5)%, or 150% of the highest dose used so far.</p>
<p>Note that a 2-fold <em>increment</em> corresponds to a 3-fold
<em>escalation</em>.</p>
<p>In tabular form, based on the dose grid defined above, the maximum
permitted escalation is</p>
<table>
<colgroup>
<col width="33%" />
<col width="33%" />
<col width="33%" />
</colgroup>
<thead>
<tr class="header">
<th align="right">Highest dose<br>administered so far</th>
<th align="right">Maximum permitted increment</th>
<th align="right">Maximum permitted dose</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="right">1</td>
<td align="right">2.0</td>
<td align="right">3.0</td>
</tr>
<tr class="even">
<td align="right">3</td>
<td align="right">6.0</td>
<td align="right">9.0</td>
</tr>
<tr class="odd">
<td align="right">9</td>
<td align="right">18.0</td>
<td align="right">27.0</td>
</tr>
<tr class="even">
<td align="right">20</td>
<td align="right">40.0</td>
<td align="right">60.0</td>
</tr>
<tr class="odd">
<td align="right">30</td>
<td align="right">45.0</td>
<td align="right">75.0</td>
</tr>
<tr class="even">
<td align="right">45</td>
<td align="right">67.5</td>
<td align="right">112.5</td>
</tr>
<tr class="odd">
<td align="right">60</td>
<td align="right">90.0</td>
<td align="right">150.0</td>
</tr>
<tr class="even">
<td align="right">80</td>
<td align="right">120.0</td>
<td align="right">200.0</td>
</tr>
<tr class="odd">
<td align="right">100</td>
<td align="right">200.0</td>
<td align="right">Not applicable</td>
</tr>
</tbody>
</table>
<p>So, if the highest dose used so far is <code>9</code>, the highest
dose in the dose grid that can be used in the next cohort is
<code>20</code>, even if <code>30</code> or higher doses are deemed safe
by the <code>NextBest</code> rule.</p>
<p>Next, we define the rule for choosing the <em>best</em> dose for the
<em>next</em> cohort</p>
</div>
<div id="the-nextbest-rule-for-recommending-the-best-dose-for-the-next-cohort" class="section level4">
<h4>The NextBest rule for recommending the best dose for the next
cohort</h4>
<div class="sourceCode" id="cb6"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb6-1"><a href="#cb6-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Choose the rule for selecting the next dose.</span></span>
<span id="cb6-2"><a href="#cb6-2" aria-hidden="true" tabindex="-1"></a>my_next_best <span class="ot">&lt;-</span> <span class="fu">NextBestNCRM</span>(</span>
<span id="cb6-3"><a href="#cb6-3" aria-hidden="true" tabindex="-1"></a>  <span class="at">target =</span> <span class="fu">c</span>(<span class="fl">0.2</span>, <span class="fl">0.35</span>),</span>
<span id="cb6-4"><a href="#cb6-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">overdose =</span> <span class="fu">c</span>(<span class="fl">0.35</span>, <span class="dv">1</span>),</span>
<span id="cb6-5"><a href="#cb6-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">max_overdose_prob =</span> <span class="fl">0.25</span></span>
<span id="cb6-6"><a href="#cb6-6" aria-hidden="true" tabindex="-1"></a>)</span></code></pre></div>
<p>Here, we choose to use Neuenschwander’s rule <span class="citation">(Neuenschwander, Branson, and Gsponer 2008)</span>, in
which the dose for the next cohort to be the dose (amongst those doses
that are eligible for selection according to the escalation rule) that
has the highest posterior chance of having a probability of toxicity in
the target range - here [0.2, 0.35) - provided that the dose’s chance of
having a probability of toxicity in the overdose range - here [0.35,
1.0] - is less than 0.25.</p>
</div>
<div id="the-cohort-size" class="section level4">
<h4>The cohort size</h4>
<p>Now, we define the rule for choosing the size of the next cohort.</p>
<blockquote>
<p>Note, the term “cohort size” is somewhat anachronistic. It is a
hangover from the days of the 3+3 design. In the context of CRM trials,
it is best interpreted as “the largest permitted interval between CRM
model updates”. In a CRM trial, the model can be updated <em>at any
time</em> and there is no mathematical need to halt recruitment to allow
the model to be updated.</p>
</blockquote>
<p>We elect to define the cohort size using a compound rule. Both the
dose to be used and the number of DLTs so far observed contribute to the
decision. The first part of the compound rule (<code>my_size_1</code>),
based on the dose to be used, permits the use a single patient run-in up
to and including a dose of <code>20</code>. For doses above
<code>20</code>, the minimum cohort size is <code>3</code>. The second
part of the compound rule (<code>my_size_2</code>) also permits a single
patient run-in, so long as no DLTs have so far been observed. As soon as
the first DLT is reported, the minimum cohort size is <code>3</code>. To
determine the <em>actual</em> size of the next cohort, the larger number
required by the two parts of the compound rule is used.</p>
<div class="sourceCode" id="cb7"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb7-1"><a href="#cb7-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Choose the rule for the cohort size.</span></span>
<span id="cb7-2"><a href="#cb7-2" aria-hidden="true" tabindex="-1"></a>my_size_1 <span class="ot">&lt;-</span> <span class="fu">CohortSizeRange</span>(</span>
<span id="cb7-3"><a href="#cb7-3" aria-hidden="true" tabindex="-1"></a>  <span class="at">intervals =</span> <span class="fu">c</span>(<span class="dv">0</span>, <span class="dv">30</span>),</span>
<span id="cb7-4"><a href="#cb7-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">cohort_size =</span> <span class="fu">c</span>(<span class="dv">1</span>, <span class="dv">3</span>)</span>
<span id="cb7-5"><a href="#cb7-5" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb7-6"><a href="#cb7-6" aria-hidden="true" tabindex="-1"></a>my_size_2 <span class="ot">&lt;-</span> <span class="fu">CohortSizeDLT</span>(</span>
<span id="cb7-7"><a href="#cb7-7" aria-hidden="true" tabindex="-1"></a>  <span class="at">dlt_intervals =</span> <span class="fu">c</span>(<span class="dv">0</span>, <span class="dv">1</span>),</span>
<span id="cb7-8"><a href="#cb7-8" aria-hidden="true" tabindex="-1"></a>  <span class="at">cohort_size =</span> <span class="fu">c</span>(<span class="dv">1</span>, <span class="dv">3</span>)</span>
<span id="cb7-9"><a href="#cb7-9" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb7-10"><a href="#cb7-10" aria-hidden="true" tabindex="-1"></a>my_size <span class="ot">&lt;-</span> <span class="fu">maxSize</span>(my_size_1, my_size_2)</span></code></pre></div>
<p>In other words, provided the dose is <code>20</code> or below and no
DLTs have been observed, a single patient cohort is permitted. In all
other cases, the required cohort size is <code>3</code>.</p>
</div>
</div>
<div id="the-stopping-rules" class="section level3">
<h3>The stopping rules</h3>
<p>Now we create the rules that define when the trial’s objectives have
been met (or when it should be stopped for futility).<br />
The futility rule is the easiest to explain: if twenty patients have
been recruited, the study should stop (<code>my_stopping_3</code>). The
success rule requires both of the following conditions to have been
met:</p>
<ul>
<li>At least three cohorts must have been treated</li>
<li>The probability that the current estimate of the MTD is in the
target toxicity range must be at least 0.5.</li>
</ul>
<p>The trial will stop of either the futility rule or <em>both</em>
components of the success rule are satisfied.</p>
<div class="sourceCode" id="cb8"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb8-1"><a href="#cb8-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Choose the rule for stopping.</span></span>
<span id="cb8-2"><a href="#cb8-2" aria-hidden="true" tabindex="-1"></a>my_stopping_1 <span class="ot">&lt;-</span> <span class="fu">StoppingMinCohorts</span>(<span class="at">nCohorts =</span> <span class="dv">3</span>)</span>
<span id="cb8-3"><a href="#cb8-3" aria-hidden="true" tabindex="-1"></a>my_stopping_2 <span class="ot">&lt;-</span> <span class="fu">StoppingTargetProb</span>(</span>
<span id="cb8-4"><a href="#cb8-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">target =</span> <span class="fu">c</span>(<span class="fl">0.2</span>, <span class="fl">0.35</span>),</span>
<span id="cb8-5"><a href="#cb8-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">prob =</span> <span class="fl">0.5</span></span>
<span id="cb8-6"><a href="#cb8-6" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb8-7"><a href="#cb8-7" aria-hidden="true" tabindex="-1"></a>my_stopping_3 <span class="ot">&lt;-</span> <span class="fu">StoppingMinPatients</span>(<span class="at">nPatients =</span> <span class="dv">20</span>)</span>
<span id="cb8-8"><a href="#cb8-8" aria-hidden="true" tabindex="-1"></a>my_stopping <span class="ot">&lt;-</span> (my_stopping_1 <span class="sc">&amp;</span> my_stopping_2) <span class="sc">|</span> my_stopping_3</span></code></pre></div>
</div>
<div id="the-overall-trial-design" class="section level3">
<h3>The overall trial design</h3>
<p>Finally, we combine all six elements of the design, together with the
starting dose, to define the trial.</p>
<div class="sourceCode" id="cb9"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb9-1"><a href="#cb9-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Initialize the design.</span></span>
<span id="cb9-2"><a href="#cb9-2" aria-hidden="true" tabindex="-1"></a>design <span class="ot">&lt;-</span> <span class="fu">Design</span>(</span>
<span id="cb9-3"><a href="#cb9-3" aria-hidden="true" tabindex="-1"></a>  <span class="at">model =</span> model,</span>
<span id="cb9-4"><a href="#cb9-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">nextBest =</span> my_next_best,</span>
<span id="cb9-5"><a href="#cb9-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping =</span> my_stopping,</span>
<span id="cb9-6"><a href="#cb9-6" aria-hidden="true" tabindex="-1"></a>  <span class="at">increments =</span> my_increments,</span>
<span id="cb9-7"><a href="#cb9-7" aria-hidden="true" tabindex="-1"></a>  <span class="at">cohortSize =</span> my_size,</span>
<span id="cb9-8"><a href="#cb9-8" aria-hidden="true" tabindex="-1"></a>  <span class="at">data =</span> empty_data,</span>
<span id="cb9-9"><a href="#cb9-9" aria-hidden="true" tabindex="-1"></a>  <span class="at">startingDose =</span> <span class="dv">3</span></span>
<span id="cb9-10"><a href="#cb9-10" aria-hidden="true" tabindex="-1"></a>)</span></code></pre></div>
<p>We are now ready to use our trial definition, either to analyse a
real trial or to simulate the long term operating characteristics of the
design. These processes are described in their own vignettes <a href="trial_analysis.html">here</a> and <a href="trial_simulation.html">here</a>.</p>
</div>
</div>
<div id="references" class="section level2 unnumbered">
<h2 class="unnumbered">References</h2>
<div id="refs" class="references csl-bib-body hanging-indent">
<div id="ref-Neuenschwander2008" class="csl-entry">
Neuenschwander, Beat, Michael Branson, and Thomas Gsponer. 2008.
<span>“Critical Aspects of the Bayesian Approach to Phase i Cancer
Trials.”</span> <em><span>Statistics in Medicine</span></em> 27 (13):
2420–39.
</div>
</div>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
